they sold directly, excersized options, and sold indirectly.....bottom line lots of selling in 2014 and no buys! This is quite pathetic and the pps will continue to drop if insiders don't begin buying!
Guys, I am long but the amount of insiders selling at these lows is discouraging and unbelievable to say the least! Tack on the short count, and I hate to say this is heading below 3s. I am now left with a tough choice of either selling and buying back in lower or continuing to add on way down....decisions, decisions, and most longs are probably considering this as well. Management needs to step up and buy significant stock!!!
This is one of the most undervalued bio plays with little risk IMO. Essentially all P1 complete with high likely hood of meeting end points for such small cohorts. Manufacturing and stability concerns would have been mitigated prior to starting these additional P1s. Pfizer has stated it intends to move forward and refile. FDA now seeks out abuse deterrent products. King and Pfizer have already validated the nPV for Remoxy amongst competition and have done due diligence on IP. Low risk with low price/valuation, seems like a no brainier. I have made my bets, solid play here and look forward to next 6-12 months to triple my investment. Ptie is not a speculative play anymore (but rather a great investment) due to risk/reward profile. Now is the time to invest prior to news being released!
Curious how folks feel about the new P2 lung cancer trial. Is this confidence that STS or Pancreatic P3 trials are going well and will meet end points or is this THLD management way of safe guarding against a negative outcome at the expense of shareholders? Small companies like this often use the latter strategy as a way to continue ops and their high salaries.....